Apellis

Apellis is now enrolling an additional 60 patients into the randomized double blind controlled part of the study corporate other highlights.

Apellis. Apls flaunted slowness of 0 97 at 31 58 as the stock market unbolted on july 22 2020. Apellis pharmaceuticals has generated 4 64 earnings per share over the last year. Minimum 15 minutes delayed. Its stock is down 0 5 year to date while the s p 500.

By pioneering targeted c3 therapies we aim to treat diseases that are driven by excessive activation of the complement cascade including those within hematology ophthalmology and nephrology. Apellis pharmaceuticals has not formally confirmed its next earnings publication date but the company s estimated earnings date is wednesday july 29th 2020 based off prior year s report dates. Data provided by refinitiv. Apellis said it plans to submit a new drug application for pegcetacoplan to the food and drug administration in the second half of the year.

In may 2020 apellis announced it had entered. Analyst opinion on apellis pharmaceuticals nasdaq apls. Is a global biopharmaceutical company that is committed to leveraging courageous science creativity and compassion to deliver life changing therapies. Apellis completes enrollment in phase 3 study of pegcetacoplan in treatment naïve patients with paroxysmal nocturnal hemoglobinuria pnh june 16 2020 apellis pharmaceuticals to present at the bmo 2020 prescriptions for success healthcare conference.

During the day the stock rose to 32 10 and sunk to 30 26 before settling in for the price of 31 89 at the close.